SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA inspects Cadila Healthcare’s API facility at Dabhasa

19 Jan 2018 Evaluate

The US Food and Drug Administration (USFDA) has completed an inspection at Cadila Healthcare’s API manufacturing facility at Dabhasa. The facility was inspected in the period from January 15, 2018 to January 19, 2018. At the end of the inspection, no observation (483) was issued.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

928.40 -7.95 (-0.85%)
21-Apr-2026 12:16 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.35
Dr. Reddys Lab 1219.90
Cipla 1232.30
Zydus Lifesciences 928.40
Lupin 2322.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×